Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

Vaccine

Volumn 33, Issue 32, 2015, Pages 4025-4034

  Penn Nicholson, Adam ^a   Geldenhuys, Hennie ^a   Burny, Wivine ^b   van der Most, Robbert ^b   Day, Cheryl L ^a,c,d   Jongert, Erik ^b   Moris, Philippe ^b   Hatherill, Mark ^a   Ofori Anyinam, Opokua ^b   Hanekom, Willem ^a   Bollaerts, Anne ^b   Demoitie, Marie Ange ^b   Kany Luabeya, Angelique Kany ^a   De Ruymaeker, Evi ^b   Tameris, Michele ^a   Lapierre, Didier ^b   Scriba, Thomas J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GSK   (Belgium)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Cytokine; M72 AS01E; NK cell; T cell; Tuberculosis; Vaccine

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; KI 67 ANTIGEN; M72 VACCINE; PHOSPHORYL LIPID A; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; QS 21; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADJUVANT SYSTEM 01; BACTERIAL ANTIGEN; CYTOKINE; DRUG COMBINATION; LIPID A; SAPONIN; SUBUNIT VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; APPLICATION SITE PAIN; APPLICATION SITE SWELLING; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOGENICITY; MALAISE; MALE; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TUBERCULOSIS; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CLINICAL TRIAL; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDEMIC DISEASE; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PATHOLOGY; STAINING; TREATMENT OUTCOME;

ADOLESCENT; ANTIGENS, BACTERIAL; CYTOKINES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDEMIC DISEASES; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRAMUSCULAR; KILLER CELLS, NATURAL; LIPID A; MALE; MYCOBACTERIUM TUBERCULOSIS; PLACEBOS; SAPONINS; STAINING AND LABELING; T-LYMPHOCYTES; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 84937516747     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.088     Document Type: Article

References (44)

1. World Health Organization Global tuberculosis report 2014 2014, World Health Organization, Geneva.
2. Soysal A., Millington K.A., Bakir M., Dosanjh D., Aslan Y., Deeks J.J., et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005, 366:1443-1451.
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. J Am Med Assoc 1994, 271:698-702.
4. Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E.M., et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014, 58:470-480.
5. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
6. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013, 34:271-286.
7. Frick M. TB vaccines pipeline 2013, June, Available from: http://www.treatmentactiongroup.org/sites/g/files/g450272/f/201306/2013%20Pipeline%20Report.pdf [accessed March 2014, Internet].
8. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10:471-486.
9. Leroux-Roels I., Leroux-Roels G., Ofori-Anyinam O., Moris P., De Kock E., Clement F., et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010, 17:1763-1771.
10. Leroux-Roels I., Forgus S., De Boever F., Clement F., Demoitié M-A., Mettens P., et al. Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013, 31:2196-2206.
11. Spertini F., Audran R., Lurati F., Ofori-Anyinam O., Zysset F., Vandepapelière P., et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis [Edinb] 2013, 93:179-188.
12. Eschen Von K., Morrison R., Braun M., Ofori-Anyinam O., De Kock E., Pavithran P., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccin 2009, 5:475-482.
13. Montoya J., Solon J.A., Cunanan S.R.C., Acosta L., Bollaerts A., Moris P., et al. A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013, 33:1360-1375.
14. Day C.L., Tameris M., Mansoor N., van Rooyen M., de Kock M., Geldenhuys H., et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013, 188:492-502.
15. Hanekom W.A., Hughes J., Mavinkurve M., Mendillo M., Watkins M., Gamieldien H., et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J Immunol Methods 2004, 291:185-195.
16. Kagina B.M., Mansoor N., Kpamegan E.P., Penn-Nicholson A., Nemes E., Smit E., et al. Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry. J Immunol Methods 2014.
17. Moris P., van der Most R., Leroux-Roels I., Clement F., Dramé M., Hanon E., et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011, 31:443-454.
18. Horowitz A., Behrens R.H., Okell L., Fooks A.R., Riley E.M. NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination. J Immunol 2010, 185:2808-2818.
19. Horowitz A., Hafalla J.C.R., King E., Lusingu J., Dekker D., Leach A., et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J Immunol 2012, 188:5054-5062.
20. Mahomed H., Hawkridge T., Verver S., Geiter L., Hatherill M., Abrahams D.A., et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int J Tuberc Lung Dis 2011, 15:331-336.
21. Jost S., Tomezsko P.J., Rands K., Toth I., Lichterfeld M., Gandhi R.T., et al. CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination. J Virol 2014, 88:8349-8354.
22. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J., Kadira B., et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185:769-778.
23. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40:279-290.
24. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010, 181:1407-1417.
25. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
26. Lindenstrøm T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182:8047-8055.
27. Aagaard C., Hoang T., Dietrich J., Cardona P-J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 2011, 369:20130437-20130447.
28. Aagaard C.S., Hoang T.T.K.T., Vingsbo-Lundberg C., Dietrich J., Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 2009, 183:2659-2668.
29. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W.B., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13:843-850.
30. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V.S., Beverley P.C.L., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181:4955-4964.
31. Derrick S.C., Yabe I.M., Yang A., Morris S.L. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011, 29:2902-2909.
32. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
33. Kagina B.M.N., Abel B., Scriba T.J., Hughes E.J., Keyser A., Soares A., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1073-1079.
34. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
35. Alcaïs A., Fieschi C., Abel L., Casanova J-L. Tuberculosis in children and adults: two distinct genetic diseases. J Exp Med 2005, 202:1617-1621.
36. Alcaïs A., Quintana-Murci L., Thaler D.S., Schurr E., Abel L., Casanova J-L. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity?. Ann N Y Acad Sci 2010, 1214:18-33.
37. Geldmacher C., Ngwenyama N., Schuetz A., Petrovas C., Reither K., Heeregrave E.J., et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010, 207:2869-2881.
38. Geldmacher C., Schuetz A., Ngwenyama N., Casazza J.P., Sanga E., Saathoff E., et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008, 198:1590-1598.
39. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572.
40. Chen C.Y., Huang D., Wang R.C., Shen L., Zeng G., Yao S., et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009, 5:e1000392.
41. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 1992, 89:12013-12017.
42. Horowitz A., Newman K.C., Evans J.H., Korbel D.S., Davis D.M., Riley E.M. Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J Immunol 2010, 184:6043-6052.
43. Fehniger T.A., Cooper M.A., Nuovo G.J., Cella M., Facchetti F., Colonna M., et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
44. He X-S., Draghi M., Mahmood K., Holmes T.H., Kemble G.W., Dekker C.L., et al. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest 2004, 114:1812-1819.